 East Setauket, March 01, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc. Nasdaq: LIXT , a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 1,133,102 shares of Lixtes common stock, at a purchase price of 3.70 per share, in a registered direct offering. The closing of the offering is expected to occur on or about March 2, 2021, subject to the satisfaction of customary closing conditions. 